PRELIMINARY RESULTS OF PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY
(PIPAC) FOR OVARIAN CANCER WITH PERITONEAL METASTASES IN TAJIKISTAN
Authors: Hojieva M. 
Published: October 2023

Relevance: Ovarian cancer is the most aggressive form among all nosologies of the female reproductive system. More than 75% of
women are diagnosed at advanced stages, and about 60% have metastases to other organs at diagnosis. Systemic chemotherapy has a
limited effect on the peritoneum and a high incidence of side effects. There is a need for more effective approaches to prolong survival and
preserve quality of life by reducing disease symptoms and treatment side effects, especially in countries with limited health resources.
The study aimed to evaluate the preliminary results of using pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients
with ovarian cancer with peritoneal metastases.
Methods: 18 women with disease stage T3a-cN0M0 treated at the Republican Cancer Research Center for 2022-2023 were studied.
The first group included six patients who underwent cytoreduction + PIPAC at the 1st stage, and the second group (12 women) underwent
ЛЕЧЕНИЕ
64 Онкология и Радиология Казахстана, №3 (69) 2023
Прозрачность исследования: Автор несет полную ответственность за содержание данной статьи.
Конфликт интересов: Автор заявляет об отсутствии конфликта интересов
Финансирование: Проведение исследования профинансировано из государственного бюджета Республики Таджикистан.
Вклад авторов: вклад в концепцию, научный дизайн, исполнение заявленного научного исследования, интерпретация
заявленного научного исследования, создание научной статьи – Ходжиева М.М.
Сведения об авторах:
Ходжиева Матлуба Музафаровна (корреспондирующий автор) – к.м.н., Руководитель отделения опухолей репродуктивной
системы женщин, Государственное учреждение «Республиканский онкологический научный центр» Министерства здравоохранения
и социальной защиты населения Республики Таджикистан, ассистент кафедры онкологии ГОУ «Институт последипломного
образования в сфере здравоохранения Республики Таджикистан», Душанбе, Республика Таджикистан, тел. +992918752100,
e-mail: 1983mat@mail.ru, ORCID ID: 0009-0005-9648-9596.
Адрес для корреспонденции: Ходжиева М.М., ГУ «Республиканский онкологический научный центр» МЗ и СЗН РТ, 734026,
Республика Таджикистан, г. Душанбе, проспект Исмоили Сомони 59а.
exploratory laparotomy + biopsy + PIPAC at the 1st stage. Patients in both groups received two courses of chemotherapy followed by a
repeat of PIPAC. Taxanes + platinum-containing drugs were used in the PIPAC process - cisplatin or carboplatin with doxorubicin. Each
patient received 2 PIPAC sessions and 4 to 6 chemotherapy courses with cytoreductive surgery. All patients underwent laparoscopic
control with a reassessment of the Peritoneal Carcinomatosis Index (PCI) by Sugarbaker (2010) and repeated biopsy of the peritoneum.
Results: The use of cytoreductive surgery + PIPAC at the first stage made it possible to level the symptoms of peritoneal carcinomatosis, to achieve a complete radiological response in 12 (67%) cases, a complete morphological response in the form of complete regression
in 44%, a moderate response in 39% of cases
Conclusion: The effectiveness of the use of PIPAC with a cytoreductive component at the first stage in the combined treatment of
ovarian cancer with peritoneal metastases has been shown in the form of improving immediate results, improving their quality of life, and
reducing the time spent in the hospital. The research is ongoing.